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ENETICALLY engineered plants and animals have become a
large part of the food we consume. The United States is the
world's largest producer of genetically modified foods, making
American consumers the most exposed population to these products.1
Patent law is one of the main contributors to this phenomenon that has
affected not only the kinds of food we eat but also the nature of the
agribusiness industry that produces these foods. Ultimately, agricultural
biotechnology patents permit the handful of companies that own the pat-
ented technologies to determine what will end up on consumers' plates.2
The patenting of food has led to concerns about the effects on individual
farmers around the world. This issue has been thoroughly explored by
other commentators3 and will not be addressed here.
This Article, however, will take on another area of concern that has
remained unexplored-the effect of these patents on independent re-
search and scientific inquiry. There is currently a void in the scientific
knowledge relating to the effects of genetically modified foods on human
health and the environment. 4 Patent law perpetuates that void by al-
lowing patent holders to control and restrict independent research in the
area. This is facilitated mostly through no-research clauses in license
agreements with farmers. This further exacerbates the problem of incom-
plete information about genetically modified foods and may ultimately
threaten public health and safety.
As the editors of Scientific American Magazine have argued, "when
scientists are prevented from examining the raw ingredients in our na-
tion's food supply or from testing the plant material that covers a large
portion of the country's agricultural land, the restrictions on free inquiry
become dangerous."' 5 While even without the involvement of the patent
law companies have economic and other incentives to perpetuate infor-
1. Agricultural Biotechnology Continues to Increase Crop Yield and Farmer Income
Worldwide While Supporting the Environment, CBS INTERACTIVE BUSINESS NETWORK
(Feb. 13, 2008), http:/lfindarticles.com/p/articles/mi-mOEIN/is_2008_Feb_13/ai-n24260354;
see also Global Status of Commercialized BiotechGM Crops: 2007, INT'L SERV. FOR THE
AcouISrmON OF AGRI-BIOTECI-t APPLICATIONS, http://www.isaaa.org/resources/publica-
tions/briefs/37/executivesummary/default.html (last visited Nov. 6, 2010).
2. See PETER PRINGLE, FOOD, INC.: MENDEL TO MONSANTo-THE PROMISES AND
PERILS OF THE BIOTECH HARVEST 5-6 (2003).
3. See, e.g., Keith Aoki, Malthus, Mendel, and Monsanto, 19 J. ENVrL. L. & LITIG.
397, 408-13, 428-30, 446-47 (2004); Vincent G. Buehler, Chapter 424: Terminating Pester-
ing Litigation, or a Paper Pesticide?, 40 McGEOROE L. REV. 355, 356-58 (2009); Dennis S.
Karjala, Biotech Patents and Indigenous Peoples, 7 MINN. J. L. Sci. & TECH. 483, 490-92,
517-18 (2006); Roger A. McEowen, Agricultural Law Developments Shaping the Sector
and Legal Practice, 14 DRAKE J. AGRIc. L. 1, 9-10 (2009).
4. Deborah B. Whitman, Genetically Modified Foods: Harmful or Helpful?, PRO-
QUEST (Apr. 2000), http://www.csa.com/discoveryguides/gmfood/review.pdf.
5. A Seedy Practice, ScI. AM., Aug. 13, 2009, at 28.
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mation gaps regarding their products, 6 patent law's specific involvement
provides an even easier and more direct way to "exclude" negative
information.
Accordingly, this Article explores whether these research restrictions
are contrary to the public interest and inconsistent with the underlying
goals of patent law. If we accept that patents support innovation, then we
must not overlook the unintended consequences of the innovation that is
supported and perpetuated by the patent laws. Using genetically modi-
fied foods as a case study for exploring this issue, this Article will raise
questions about whether the patent system bears any social responsibility
to consumers. As the gatekeepers to new technologies, should the patent
law concern itself with the consequences of the innovation it fosters? The
broader public policy issue at the backdrop of this problem represents the
struggle to reconcile the rights of patent owners with the public interest,
when such patent rights may endanger public health and safety. This ten-
sion has been explored in other contexts. The patenting of human genes,
for instance, raises similar questions and has received much attention in
the literature.7
The research restrictions associated with the patenting of genetically
modified foods, however, have not been explored. This Article not only
introduces and analyzes the specific problems caused by the no-research
restrictions but situates the issue in the larger context of intellectual prop-
erty overreaching. As the Supreme Court has recognized, "Congress in
the exercise of the patent power may not overreach the restraints im-
posed by the stated constitutional purpose. Nor may it enlarge the patent
monopoly without regard to the innovation, advancement or social bene-
fit gained thereby."' 8 Accordingly, to the extent the license restrictions at
issue here are supported by or grounded in patent law, it becomes the
responsibility of courts interpreting the law to take a more equitable ap-
proach in balancing these overarching patent policy tensions.
The next Part discusses the interconnection between and among agri-
culture, technology, and intellectual property. It provides relevant back-
ground on the evolution of the patenting of genetically modified foods as
well as the public concerns regarding these foods. Part III identifies the
specific patent policies that are implicated as well as the nature of the
research restrictions and regulatory shortcomings associated with geneti-
6. See Wendy E. Wagner, Commons Ignorance: The Failure of Environmental Law to
Produce Needed Information on Health and the Environment, 53 DUKE L.J. 1619, 1634-41(2004).
7. See, e.g., Russel Lawrence Barsh, Pharmacogenomics and Indigenous Peoples:
Real Issues and Actors, 11 CARDOZO J. INT'L & COMP. L. 365, 365-66 (2003); Timothy
Caulfield, Human Gene Patents: Proof of Problems?, 84 CHi.-KENT L. REV. 133, 133
(2009); Eileen M. Kane, Molecules and Conflict: Cancer, Patents, and Women's Health, 15
AM. U. J. GENDER Soc. POL'Y & L. 305, 307 (2007); Jordan Paradise, European Opposi-
tion to Exclusive Control Over Predictive Breast Cancer Testing and the Inherent Implica-
tions for U.S. Patent Law and Public Policy: A Case Study of the Myriad Genetics' BRCA
Patent Controversy, 59 FooD & DRUG L.J. 133, 137-34 (2004).
8. Graham v. John Deere Co. of Kansas City, 383 U.S. 1, 5-6 (1966).
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cally modified foods. It compares the treatment of pharmaceuticals to
that of genetically modified foods to underscore the greater potential for
harm that arises from restricting research on genetically modified foods.
Part IV argues that the patent law's role in limiting access and restricting
research goes too far, contrary to the public interest and the underlying
goals of patent law. It suggests that courts use a "patent overreach" doc-
trine to rein in these restrictions. Finally, the Article concludes in Part V
that, on balance, the public interest in promoting independent research
on the health and safety effects of foods should outweigh the patent
holder's interest in controlling the state of adverse information available
about its product.
II. AGRICULTURE, TECHNOLOGY, AND
INTELLECTUAL PROPERTY
Technological innovations in agriculture have led to many advances
that have helped make farming more efficient and productive. They
have, for instance, enabled the use of less land to produce more food and
the use of fewer pesticides sprayed directly onto crops.9 The first biotech
food appeared in the United States market in 1995.10 Today, almost the
entire crop of corn and soybeans in the United States is genetically modi-
fied. 1 However, this development did not happen overnight, and the in-
volvement of science, intellectual property protection, and government
regulation is an important part of the story of its evolution.
A. BRIEF HISTORY
A brief history of the progression of agricultural biotechnology to to-
day shows the increasing involvement of intellectual property protection
with each step in scientific advancement. As the remainder of this Part
will discuss, during the open-pollination period, when the wind and in-
sects did the work, 12 there was little need for protection. Later, as hybrid
seeds were introduced, trade secret law allowed seed producers to protect
their proprietary information. 13 In 1930, Congress recognized the impor-
9. A Seedy Practice, supra note 5, at 28.
10. Factsheet: Genetically Modified Crops in the United States, PEW INITIATIVE ON
FOOD AND BIOTECHNOLOGY (Aug. 2004), http://www.pewtrusts.org/uploadedFiles/www
pewtrustsorg/Fact-Sheets/Food-and-Biotechnology/PIFB-Genetically-Modified-Crops-
Factsheet0804.pdf.
11. Bruce Stutz, Companies Put Restrictions on Research into GM Crops, YALE ENV'T
360 (May 13, 2010), http://www.e360.yale.edu/content/print.msp?id=2273.
12. Debra L. Blair, Intellectual Property Protection and Its Impact on the U.S. Seed
Industry, 4 DRAKE J. AGRIC. L. 297, 304 n.72 (1999).
13. McEowen, supra note 3, at 9; see Jeremy P. Oczek, Note, In the Aftermath of the
"Terminator" Technology Controversy: Intellectual Property Protections for Genetically
Engineered Seeds and the Right to Save and Replant Seed, 41 B.C. L. REV. 627, 632 (2000)
("Breeding plants through the hybridization process involves selecting and reproducing
plants with favorable characteristics while rejecting plants with undesirable traits. Using
hybrid crosses between various inbred lines, seed developers can sell seed that produces
hybrid plants, but which in turn does not reproduce hybrids.").
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tance of affording patent-like protection to plants.14 Finally, in 2001,
plants were deemed entitled to full patent protection in the form of utility
patents. 15 Today, the technological advancements that create genetically
modified foods are protected by utility patents.16 It is the bundle of rights
associated with these patents that has helped shape the agribusiness in-
dustry as well as the level of control exerted over the production and the
state of knowledge surrounding genetically modified foods.
1. Hybrid Seeds and Trade Secrets
In the beginning, seed production did not involve technology. Crops
were pollinated by nature using wind or insects. 17 Over time, seed pro-
ducers were able to produce hybrid seeds using manual pollination. 18
Plants grown from these hybrid seeds exhibited enhanced characteristics
such as greater yield or disease resistance not exhibited in either of the
parent-inbred lines. 19 However, while the first generation of hybrid seeds
consistently produced plants with desired characteristics, the subsequent
generations that were the product of open pollination in the farmers'
fields produced inconsistent and undesirable characteristics. 20 Thus, hy-
brid seeds were only useful for the first generation, and farmers had to
buy new hybrid seeds each planting season from the seed producers. 2 '
The ability to sell hybrid seeds to farmers without releasing the parent
inbred lines allowed private seed producers to keep the parent inbred
lines as trade secrets, thus conducting business and research under the
protection of trade secret law.22
The first hybrid corn seed was marketed in 1926 by Hi-Bred Corn
Company (which later became Pioneer Hi-Bred International Inc.) in
Des Moines, Iowa.23 During the 1930s, hybrid seed corn gained increas-
ing acceptance among farmers, "and by 1943, virtually one hundred per-
cent of the corn planted in Iowa and ninety percent of the corn planted in
14. Benjamin Ikuta, Genetically Modified Plants, Patents, and Terminator Technology:
The Destruction of the Tradition of Seed Sharing, 35 OHIo N.U. L. REV. 731, 734-35
(2009).
15. Keith Aoki, Seeds of Dispute: Intellectual-Property Rights and Agricultural Bi-
odiversity, 3 GOLDEN GATE U. ENvIn. L.J. 79, 102-03 (2009).
16. Id. at 103.
17. Blair, supra note 12, at 304 n.72 (quoting JOHN MILTON POEHLMAN, BREEDING
FIELD CROPS 20 (3d ed. 1987) ("Open-pollination, also known as natural cross pollination,
is the transfer of pollen by such means as the wind or insects from the anther on one plant
to the stigma or silk of another plant.").
18. See Keith Aoki, Weeds, Seeds & Deeds: Recent Skirmishes in the Seed Wars, 11
CARDOZO J. INT'L & CoMP. L. 247, 269 (2003); see Blair, supra note 12, at 305.
19. See Aoki, supra note 18, at 270; Blair, supra note 12, at 305 (noting that these
inbred lines were homozygous and thus would produce nearly identical plants generation
after generation through self pollination).
20. See Aoki, supra note 18, at 271; Blair, supra note 12, at 305.
21. See Aoki, supra note 18, at 271.
22. See Aoki, supra note 18, at 281; Blair, supra note 12, at 306-10; see also Keith D.
Parr, Developments in Agricultural Biotechnology, 19 WM. MITC-HELL L. REv. 457, 469-72
(1993) (discussing Pioneer Hi-Bred Int'l, Inc. v. Holden Found. Seeds, Inc., No. 81-60-E,
1987 WL 341211 (S.D. Iowa Oct. 30, 1987)).
23. Blair, supra note 12, at 305.
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the U.S. Corn Belt was hybrid seed corn."'2 4 Representing a $70 million
market by 1944, corn seed was established "as the core business of the
U.S. seed industry. '25
2. Introduction of Patent-Like Protection for Plants
In 1930, Congress passed the Townsend-Purnell Plant Patent Act of
1930 (PPA) 26 to provide a patent-like system for protecting plants.27 The
PPA was the first legislation of its kind in the world to grant intellectual
property rights to breeders28 who had "invented or discovered and asexu-
ally reproduced any distinct and new variety of plant, other than a tuber-
propagated [sic] plant."'29 The Act defines asexual reproduction to in-
clude reproduction "by means other than from seeds, such as by the root-
ing of cuttings, by layering, budding, grafting, in-arching, etc."'30
Congress created the PPA to provide breeders of new asexually propa-
gated plant varieties with incentives and protections similar to those pro-
vided by utility patents. 31 Infringement occurs when the accused plant "is
a direct or indirect asexual reproduction of the patentee's original pat-
ented parent plant."'32 There is no infringement when one sexually repro-
duces the patented plant.33
In 1970, Congress expanded the intellectual property protection af-
forded to plants by enacting the Plant Variety Protection Act (PVPA).34
Prior to the enactment of the PVPA, hybrid-seed companies enjoyed
trade-secret protection over the plant varieties they developed but, as dis-
cussed above, were not eligible for the patent-like protection of the
PPA.35 The PVPA, through the issuance of a plant variety certificate,
confers exclusive rights to "[t]he breeder of any sexually reproduced or
tuber propagated plant variety (other than fungi or bacteria) who has so
reproduced the variety .... -136 PVP certificates are issued by the Depart-
ment of Agriculture-not the PTO.37
Unlike the earlier Plant Patent Act, the PVPA contained two signifi-
24. Id.
25. JORGE FERNANDEZ-CORNEJO, U.S. DEP'T OF AGRIc., THE SEED INDUSTRY IN
U.S. AGRICULTURE: AN EXPLORATION OF DATA AND INFORMATION ON CROP SEED MAR-
KETS, REGULATION, INDUSTRY STRUCTURE, AND RESEARCH AND DEVELOPMENT 25 (ERS
Agric. Info. Bull. No. 786, 2004), available at http://www.ers.usda.gov/publications/aib786/
aib786.pdf.
26. 35 U.S.C. § 161 (2006).
27. Aoki, supra note 15, at 96.
28. Id.
29. 8 DONALD S. CHISUM, CHISUM ON PATENTS § 24.02(1) (2010).
30. Id. § 24.02(2)(b).
31. See Aoki, supra note 15, at 96-97.
32. Id.
33. CHISUM, supra note 29, § 24.02(4).
34. Plant Variety Protection Act, Pub. L. No. 91-577, 84 Stat. 1542 (1970) (codified as
amended in scattered sections of 7 and 28 U.S.C.).
35. FERNANDEZ-CORNEJO, supra note 25, at 25-26.
36. 7 U.S.C. § 2402(a) (2006).
37. FERNANDEZ-CORNEJO, supra note 25, at 21.
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cant exemptions: one for crops and the other for research. 38 The crop
exemption allows crops grown from protected varieties to be sold as food,
feed, fiber, or for other nonreproductive purposes.39 Additionally, the
crop exemption allows farmers to save seed produced from protected va-
rieties for replanting the next season on their own farm.40 Between its
enactment in 1970 and 1994, the crop exemption also allowed farmers
whose primary farming business was growing crops for nonreproductive
purposes to sell saved seed grown from protected varieties for reproduc-
tive purposes.41 In 1994, Congress repealed the provisions of the PVPA's
crop exemption that allowed farmers to sell their saved seed to others.42
In its current form, the crop exemption allows farmers to sell seed for
nonreproductive purposes and to save seed for planting on their own
farms.43 Notably, the PVP certificate contains a research exemption, ex-
plicitly providing that "[t]he use and reproduction of a protected variety
for plant breeding or other bona fide research shall not constitute an in-
fringement of the protection provided under this chapter. '44 It is inter-
esting that, unlike the crop exemption, Congress has chosen not to repeal
or amend this provision.
3. Enter Genetically Modified Seeds and Utility Patents
In 1980, the United States Supreme Court recognized the patentability
of living organisms in its landmark case Diamond v. Chakrabarty.45 The
Court ruled in Chakrabarty that a living bacterium "was patentable sub-
ject matter because (1) it was a product of creative human agency con-
taining characteristics 'markedly different' from those found in nature,
and (2) it possessed potential for significant utility."'46 In light of the deci-
sion in Chakrabarty, the U.S. Patent Office wrestled with whether utility
patents could cover sexually reproduced plants.47 The U.S. Board of Pat-
ent Appeals and Interferences concluded that the PVPA did not prevent
application of patent protection to such plants.48 Finally, in 2001, the
U.S. Supreme Court confirmed that utility-patent protection extended to
sexually and asexually reproduced plants.49 These cases paved the way
for the introduction and patenting of genetically modified seed in
agriculture.
38. Jim Chen, The Parable of the Seeds: Interpreting the Plant Variety Protection Act in
Furtherance of Innovation Policy, 81 NOTRE DAME L. REV. 105, 124 (2005) (discussing the
PVPA research exemption).
39. Id. at 127.
40. Id.
41. Id. at 128.
42. Id. at 129.
43. Id. at 131.
44. 7 U.S.C. § 2544 (2000); see also Chen, supra note 38, at 132-39.
45. 447 U.S. 303, 310 (1980).
46. Aoki, supra note 15, at 102 (citing Chakrabarty, 447 U.S. at 310).
47. See Ex parte Hibberd, No. 645-91, 227 U.S.P.Q. (BNA) 443, 444 (B.P.A.I. 1985).
48. Id. at 444-45.
49. J.E.M. AG Supply, Inc. v. Pioneer Hi-Bred Int'l, Inc., 534 U.S. 124, 145-46 (2001).
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B. FROM PATENTS TO SUPERMARKETS
About seventy percent of the food available in American supermarkets
contains genetically modified substances. 50 The United States is the top
producer of genetically modified crops, followed by Brazil, Argentina, In-
dia, and Canada.51 The vast majority of corn grown in the United States,
eighty percent, is genetically modified, 52 and about a quarter of the prod-
ucts in the supermarket contain corn.53 These corn-containing products
span an array that may surprise most consumers-from high-fructose
corn syrup in beverages to ketchup, cake mixes, syrups, margarine, salad
dressing, and vitamins.54
The three companies leading the biotech food products industry are
Monsanto, DuPont's Pioneer Hi-Bred, and Syngenta.5 5 "These three
companies develop most of the new [genetic cross bred] traits [in the in-
dustry] and license them to each other, smaller seed companies, and pub-
lic breeding programs. ' 56 Monsanto alone sold $7.3 billion of seeds and
seed genes in 2009, placing first among its competitors. 57 Indeed, Mon-
santo seeds dominate. "Ninety percent of the U.S. soybean crop and
80% of the corn crop and cotton crop are grown with seeds containing
Monsanto's technology."15 8 The company focuses largely on corn, cotton,
and soybean crops rather than on a wider variety of crops because these
are more likely to generate a large enough return on its investment in
biotechnology. 59 While traditionally, genetic material was transferred be-
tween the same species (e.g., plant to plant), genetic engineering technol-
ogy now permits transfers between and among any genus or species.60
50. How Consumers Process Information at the Heart of Debate Over Labeling of Ge-
netically Modified Foods, PEW CHARITABLE TRUSTS (June 27, 2002), http://www.pewtrusts.
org/newsroom detail.aspx?id=33460.
51. See James Kanter, In Europe, a Move to Ease Curbs on Growing Biotech Crops,
N.Y. TIMES, July 8, 2010, at B4.
52. NAT'L AGRIC. STATISTICS SERV., U.S. DEP'T OF AGRIC., ACREAGE 32 (June 30,
2008), available at http://usda.mannlib.cornell.edu/usda/current/Acre/20OOs/2008/Acre-06-
30-2010.pdf. In 2008, 92% of soybeans grown in the United States are genetically modi-
fied. Id. at 34.
53. MICHAEL POLLAN, THE OMNIVORE'S DILEMMA: A NATURAL HISTORY OF FOUR
MEALS 19 (2006).
54. Id. at 18-19.
55. Elizabeth I. Winston, What Ifs and Other Alternative Intellectual Property and
Cyberlaw Story: If Seeds Were Not Patentable?, 2008 MICH. ST. L. REV. 321, 329 n.45
(2008).
56. Id.
57. Robert Langreth & Matthew Herper, The Planet Versus Monsanto, FORBES, Jan.
18, 2010, at 64.
58. Id.
59. Id. at 69. Because genetically modified corn and soybeans are not often sold di-
rectly to consumers they are "less controversial." Id.
60. See, e.g., Statement of Policy: Foods Derived from New Plant Varieties, 57 Fed.
Reg. 22,984, 22,986 (May 29, 1992); Charles W. Schmidt, Genetically Modified Foods:
Breeding Uncertainty, ENVTL. HEALTH PERSP. (Aug. 1, 2005), http://www.ncbi.nlm.nih.gov/
pmc/articles/PMC1280366/pdf/ehpOll3-a00526.pdf.
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Thus, for example, both a tomato 61 and a pig62 can contain genes from a
fish. The crossing of traits carries many benefits that before now were
not possible. It can increase nutritional value63 (e.g., rice containing beta-
carotene), 64 freshness for storage (e.g., tomatoes containing a fish gene to
reduce rotting),65 and resistance to insects and pests.66
In the early 1980s,67 researchers at Monsanto discovered a break-
through method for producing biotech crops. Rather than inserting new
genes into plant cells with a gene gun, they discovered that bacteria (in-
serted with the desired genes) mixed in a Petri dish with plant cells was a
more effective method. 68 That method is still widely used today. 69
Roundup Ready® soybeans were developed and patented by Mon-
santo.70 These soybeans have been genetically altered to resist the herbi-
cide Roundup. 71 The advantage of the Roundup Ready® soybeans is
that spraying the field to kill weeds will not kill the soybean plants.72
Corn has also been genetically engineered to carry genes from Bacillus
thuringiensis (BT), a naturally occurring soil bacterium that produces a
protein toxic to some insects.73
The advancements continue. Monsanto is currently working on a ge-
netically modified soybean that would contain high levels of omega-3
fatty acids; these fish-based fatty acids have been shown to promote a
healthy heart.74 Additionally, on a more aesthetic note, in Israel, gene
technology is being used to create exotic "designer" fruits and vegetables
to entice consumers: tomatoes that smell like lemons, carrots shaped like
potatoes, strawberries shaped like carrots, and blue bananas. 75 It proba-
bly will not be long before these products land in United States
supermarkets.
Beyond genetically engineered crops, as this Article is being prepared,
the Food and Drug Administration (FDA) is in the process of reviewing
61. Schmidt, supra note 60.
62. See Liangxue Lai et al., Generation of Cloned Transgenic Pigs Rich In Omega-3
Fatty Acids, 24 NATURE BIOTECHNOLOGY 435-36 (Apr. 2006), available at http://www.na-
ture.com/nbt/journal/v24/n4/pdf/nbt1l98.pdf.
63. See, e.g., NATIONAL RESEARCH COUNCIL, GENETICALLY MODIFIED PEST-PRO-
TECTED PLANTS: SCIENCE AND REGULATION 35 (2000).
64. Biotech Crop Roundup: Stars-and Failures-in the Field of Genetically Modified
Crops, NPR (Nov. 15, 2001), http://www.npr.org/programs/morning/features/2001/nov/bi-
otech/011115.crops.html.
65. Id.
66. John Charles Kunich, Mother Frankenstein, Doctor Nature, and the Environmental
Law of Genetic Engineering, 74 S. CAL. L. REV. 807, 810-11 (2001).
67. Langreth & Herper, supra note 57, at 64.
68. Id.
69. Id.
70. See Monsanto Co. v. McFarling (McFarling 11), 363 F.3d 1336, 1338-39 (Fed. Cir.
2004) (holding that the soybeans are covered by U.S. Patent Nos. 5,633,435 and 5,352,605).
71. Jay P. Kesan, Licensing Restrictions and Appropriating Market Benefits from Plant
Innovation, 16 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 1081, 1082-83 (2006).
72. Id. at 1083.
73. Langreth & Herper, supra note 57, at 67.
74. Id.
75. Edmund Sanders, Yes, We Have Blue Bananas, L.A.TIMES, May 29, 2010, at Al.
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the first genetically altered animal for our kitchens-salmon.76
AquaBounty Technologies, the salmon's developer, wishes to create and
sell eggs that have been genetically modified to produce salmon that grow
twice as fast as conventional Atlantic salmon. 77 It contains a growth hor-
mone from a Chinook salmon and genetic material from another kind of
fish, the ocean pout, that permits the growth hormone to be released year
round, unlike nonengineered salmon, which do not produce growth hor-
mone in cold weather.78 Not surprisingly, this salmon appears to be pat-
ented. 79 While its nutritional content is claimed to be identical to its
naturally occurring counterpart, the genetically modified salmon takes
eighteen months to grow and mature rather than the usual three years. 80
Interestingly, it is not entirely clear whether the FDA, under the current
regulations, has the authority to review this genetically altered salmon,
and it is possible that its authority could be challenged.81 Nevertheless, if
this salmon is approved, it would be the first genetically modified animal
approved for human consumption.8 2 However, like genetically modified
corn and other crops, it will not be labeled.83
C. PUBLIC HEALTH CONCERNS AND THE UNKNOWN
The possible health consequences of genetically modified foods are
currently unknown. While many possible concerns have been identified,
the state of research is incomplete and inconclusive. When DNA from a
donor food is added to a host food, the DNA also adds a foreign protein
to the host food product.84 This could mean, for instance, that genetic
engineering can transfer allergens from a food to which someone is aller-
gic (e.g., nuts) to a food to which she has no known allergies (e.g., soy-
beans) without her being aware of the change, and thus may cause her to
76. Editorial, First, Grill Robo-Salmon's Producers-and the FDA, THE OREGONIAN
(July 7, 2010, 6:23 PM), http://www.oregonlive.com/opinion/index.ssf/2010/07/first-grill-
robo-salmons-produ.html.
77. Id.
78. Andrew Pollack, Genetically Altered Salmon Set to Move Closer to Dinner Table,
N.Y. TIMES, June 26, 2010, at Al.
79. See U.S. Patent No. 5,545,808 (filed Mar. 10, 1994) (Transgenic salmonid fish ex-
pressing exogenous salmonid growth hormone); U.S. Patent No. 5,480,774 (filed Oct. 14,
1993) (Determination of genomic sex in salmonids).
80. Pollack, supra note 78, at Al.
81. See Gregory N. Mandel, Gaps, Inexperience, Inconsistencies, and Overlaps: Crisis
in the Regulation of Genetically Modified Plants and Animals, 45 WM. & MARY L. REV.
2167, 2209 (2004). Because the genetic modification of the salmon involves increased pro-
duction of its growth hormone it would seem that, consistent with the FDA's position on
the insertion of genetic material, it should be treated as GRAS and not require approval.
However, in this instance the FDA is treating it as a "new animal drug" under the Food,
Drug, and Cosmetic Act. Id.; see also discussion infra at Part III.C.
82. Editorial, supra note 76.
83. See id.; see also Pollack, supra note 78, at Al.
84. See LUCA BUCCHINI & LYNN R. GOLDMAN, A SNAPSHOT OF FEDERAL RESEARCH
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suffer serious, potentially life-threatening reactions. 85 The incidence of
food allergies is reportedly on the rise.86 However, there is insufficient
data to determine the relationship between the increase in allergies and
the use of biotech foods.87
Part of the challenge in identifying possible links to health conse-
quences is that given the nature of these genetically modified products
and how they are used, it is more difficult to identify and measure conse-
quences and to correlate them to the source.88 If a consumer eats a ge-
netically modified food and becomes ill or has an allergic reaction to it,
he or she is unlikely to even be aware that he or she consumed a geneti-
cally modified product (given the absence of labeling), and the incident
may never be connected to the consumption. 89 This means that it will
probably require a longer span of time over which to quantify and deter-
mine health consequences. Accordingly, the current state of affairs is
probably best described as an "information void" where we do not have
enough information to determine the extent of unintended health and
environmental consequences. 90
The use of genetic engineering does not in itself create inherent health
risks. 91 However, the possibility of health hazards cannot yet be ruled
out, and there is a lot that we simply do not know. A few studies that
have been performed on animals reveal potentially negative health out-
comes in rats from genetically modified foods.92 For instance, genetically
modified potatoes have reportedly damaged rats' organs, including their
brains, livers, and testicles. 93 Similarly, rats fed genetically modified to-
matoes and corn also developed multiple negative reactions. 94 High fruc-
tose corn syrup, which is found in most beverages that Americans
consume and which is mostly made from genetically modified corn, has
85. See Julie A. Nordlee et al., Identification of a Brazil-Nut Allergen in Transgenic
Soybeans, 334 NEW ENG. J. MED. 688, 688 (1996). On the flip side, genetic engineering
may allow for the removal of allergens from food products. See Andrew Pollack, Gene
Jugglers Take to Fields for Food Allergy Vanishing Act, N.Y. TIMES, Oct. 15, 2002, at F2
(discussing the possibility of actually deleting allergens from foods like wheat and
peanuts).
86. Hugh A. Sampson et al., Fatal and Near-Fatal Anaphylactic Reactions to Food in
Children and Adolescents, 327 NEW ENG. J. MED. 380, 384 (1992) ("It is our belief and that
of other investigators studying food allergy that the frequency of fatal and near-fatal food-
induced [allergic] reactions has risen over the past several years."); Susan Dominus, The
Allergy Prison, N.Y. TIMES, June 10, 2001, § 6 (Magazine), at 63.
87. See BUCCHINI & GOLDMAN, supra note 84, at 9.
88. See Katharine A. Van Tassel, Genetically Modified Plants Used for Food, Risk As-
sessment and Uncertainty Principles: Does the Transition from Ignorance to Indeterminacy
Trigger the Need for Post-Market Surveillance?, 15 B.U. J. Sci. & TECH. L. 220, 246 (2009).
89. Id.
90. Id. at 229.
91. PRINGLE, supra note 2, at 5.
92. See generally Jeffrey M. Smith, GENETIC ROULETrE: THE DOCUMENTED HEALTH
RISKS OF GENETICALLY ENGINEERED FOODS (2007).
93. Id. at 23.
94. Id. at 25-29; Katherine Goldstein & Gazelle Emami, Monsanto's GMO Corn




also recently been linked to potential liver problems in humans.95 How-
ever, because each of these studies was limited, further research and in-
vestigation is required to better determine health risks.
There are also concerns about possible harm to the environment from
genetically modified crops. There is a risk that genetically engineered
plants containing insecticides may cause the insect population to become
resistant to these pesticides.96 Furthermore, genetically modified herbi-
cide-resistant plants may cause farmers to use more toxic chemicals as
they increase the amount of herbicides sprayed on weeds, knowing that
the herbicide will not affect the plants.97 Cross-contamination is also a
potential problem as genetically modified crops can contaminate non-ge-
netically modified crops,98 and genetically modified products not meant
for human consumption can inadvertently enter the food supply. 99 In
September 2000, for instance, StarLink corn, a genetically engineered
strain of corn not approved for human consumption, was found in Taco
Bell-brand taco shells as well as in other human food products, and all of
the shells had to be recalled.100
III. PATENT RESTRICTIONS, FOOD, AND THE CONSUMER
Patent law supports innovation. That is the mantra that justifies the
power of a patent and the resulting monopoly associated with it.101 While
some scholars disagree about the extent to which innovation would be
stifled without a strong patent system, patenting and innovation go hand
in hand. This phenomenon has wide-reaching effects that move beyond
95. Melissa Healy, High-Fructose Corn Syrup Consumption May Push Fatty Livers to
the Brink, L.A. TIMES (Mar. 18, 2010, 6:12 PM), http://latimesblogs.latimes.comlbooster
shots/2010/03/high-fructose-corn-syrup-consumption-may-push-fatty-livers-to-the-brink.
html?.
96. See First Documented Case of Pest Resistance to Biotech Cotton, SCIENCEDAILY
(Feb. 8, 2008), http://www.sciencedaily.comlreleases/2008/02/080207140803.htm (discussing
the bollworm's developed resistance to Bt cotton).
97. Michael A. Whittaker, Comment, Reevaluating the Food and Drug Administra-
tion's Stand on Labeling Genetically Engineered Foods, 35 SAN DIEGO L. REV. 1215, 1220
(1998).
98. See GREENPEACE INT'L, GM CONTAMINATION REGISTER REPORT 2007, at 5
(2008), http://www.greenpeace.org/international/en/publications/reports/gym-contamina-
tion-register-2007/ (follow "Download document" hyperlink).
99. In the last ten years, over two hundred incidents have been recorded involving this
kind of contamination into the food supply. Id. at 11. In one incident, piglets modified
with cow genes to increase milk production and a synthetic gene were accidentally sold for
use in consumer pork products. Shelley Smithson, Eat, Drink and Be Wary: Genetically
Modified Animals Could Make It to Your Plate with Minimal Testing-and No Public In-
put, GRIST (July 30, 2003, 9:00 AM), http://www.grist.org/article/and3.
100. See Barnaby J. Feder, Companies Act to Keep Bioengineered Corn Out of Food,
N.Y. TIMES, Sept. 27, 2000, at C2; Andrew Pollack, Kraft Recalls Taco Shells with
Bioengineered Corn, N.Y. TIMES, Sept. 23, 2000, at C1. See generally ALEJANDRO E.
SEGARRA & JEAN M. RAwSON, STARLINK TM CORN CONTROVERSY: BACKGROUND (Jan. 10,
2001), available at http://www.ncseonline.org/nle/crsreports/agriculture/ag-101.cfm.
101. See ROBERT P. MERGES ET AL., INTELLECTUAL PROPERTY IN THE NEW TECHNO-
LOGICAL AGE 127 (rev. 4th ed. 2006).
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intellectual property and into the business arena.102 Patents are tied to
our economic development, and the ownership of patents has strong im-
plications for companies large and small and the industries in which they
operate. 10 3 Because patenting has such a strong influence on business
and industry, and ultimately on consumers, patent law and policy should
not be viewed in isolation or as a discrete field belonging only to intellec-
tual property laws but in a larger context that takes into consideration the
broader effect of patents after they have been granted.
Under § 101 of the Patent Act, "[w]hoever invents or discovers any
new and useful process, machine, manufacture, or composition of matter,
or any new and useful improvement thereof, may obtain a patent there-
fore, subject to the conditions and requirements [of the Act]. ' 10 4 Ac-
cording to the Constitution, the patent system is meant to promote the
progress of science.' 0 5 It does so by providing an incentive to invest in
innovation.10 6 Patents allow the patent holder to exclude others from
practicing an invention unless permission has been granted, often through
a license. Monsanto, for instance, receives an estimated $500 million in
royalties from licensing its Roundup Ready® soybean seed.10 7
In determining whether an invention has met the many requirements
of the Patent Act, there is no place for considering possible consequences
of using the invention.'0 8 The closest category might be the consideration
of utility or usefulness. 10 9 However, for most inventions the utility re-
quirement does not make value judgments or moral judgments nor does
it present much of a hurdle as the courts have interpreted it to be satisfied
as long as the invention can be put to some lawful purpose.110
A. RESTRICTIONS ON SAVING SEEDS
It used to be that companies had to rely on the Plant Variety Protection
Act (PVPA) for protection.1' 1 The PVPA offered patent-like protection
for sexually reproduced seeds, but it allowed farmers to save seeds for
replanting."12 In J.E.M. AG Supply, Inc. v. Pioneer Hi-Bred Interna-
tional, Inc., the Court held that plant materials could be protected by util-
ity patents, which offer stronger protection, and thus the PVPA was no
102. See Steve LeVine, IBM May Not Be the Patent King After All, BLOOMBERG Busl-
NESSWEEK (Jan. 13, 2010, 6:12 PM), http://www.businessweek.com/magazine/content/10-
04/b4164051608050.htm.
103. See id.
104. 35 U.S.C. § 101 (2006).
105. U.S. CONST. art. I, § 8, cl. 8.
106. Kewanee Oil Co. v. Bicron Corp., 416 U.S. 470, 480-81 (1974); MERGES ET AL.,
supra note 101, at 127.
107. Langreth & Herper, supra note 57, at 69.
108. See Margo A. Bagley, Patent First, Ask Questions Later: Morality and Biotechnol-
ogy in Patent Law, 45 WM. & MARY L. REV. 469, 490-93 (2003) (noting that the U.S.
patent system does not consider moral utility for biotech inventions).
109. Id.
110. See Juicy Whip, Inc. v. Orange Bang, Inc., 185 F.3d 1364, 1367-68 (Fed. Cir. 1999).
111. See J.E.M. AG Supply, Inc. v. Pioneer Hi-Bred Int'l, Inc. 534 U.S. 124,127 (2001).
112. Plant Variety Protection Act, 7 U.S.C. § 2543 (2006).
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longer the exclusive means of protection. 113 Accordingly, when seeds are
covered by a utility patent, a farmer who saves seeds in violation of an
agreement with the manufacturer is infringing the patent.114
Seed producers use license restrictions called "bag tag" or "seed wrap
licenses" on bags of seed. 1 5 They often require farmers to sign a technol-
ogy agreement in which, among other things, they acknowledge that the
seeds are protected by a patent and that saving or reselling them is pro-
hibited.116 A Pioneer "bag tag" license reads:
[I]f the tag indicates this product or the parental lines used in pro-
ducing this product are protected under one or more US patents,
Purchaser agrees that it is granted a limited license thereunder only
to produce forage, or grain for feeding or processing. Resale of this
seed or supply of saved seed to anyone, including Purchaser, for
planting is strictly prohibited under this license. 117
Monsanto's seeds are distributed through authorized seed distributors
who have signed contracts containing restrictions including that the dis-
tributor can only license the seed to the grower but not sell it.118 Mon-
santo requires seed companies to enter into licenses or technology
agreements with each purchaser or farmer.'1 9 Under the Monsanto
agreement, the farmers must agree:
To use the seed containing the Monsanto gene technologies for
planting a commercial crop only in a single season. To not supply
any of this seed to any other person or entity for planting, and to not
save any crop produced from this seed for replanting, or supply
saved seed to anyone for replanting. To not use [the] seed or provide
it to anyone for crop breeding, research, generation of herbicide re-
gistration data or seed production. 120
Sometimes these "agreements" are mere notices on the products rather
than a document that the licensee has to sign, acknowledging the terms
and granting consent.' 21 However, the Court of Appeals for the Federal
Circuit has upheld the validity of these license notices unless they were
"objected to within a reasonable time."' 22 However, note that these
113. J.EM. AG Supply, Inc., 534 U.S. at 129, 143 ("Utility patents issued for plants do
not contain such [seed saving] exemptions" and "utility patent holders receive greater
rights of exclusion" for having met "more stringent requirements.").
114. See McFarling II, 363 F.3d 1336, 1342-43 (Fed. Cir. 2004).
115. Mark D. Janis & Jay P. Kesan, Intellectual Property Protection for Plant Innova-




118. Winston, supra note 55, at 331.
119. McFarling 11, 363 F.3d at 1339.
120. Id.
121. See, e.g., Pioneer Hi-Bred Int'l, Inc. v. Ottawa Plant Food, Inc., 283 F. Supp. 2d
1018, 1024 (N.D. Iowa 2003) (notice on bags of corn).
122. Mallinckrodt, Inc. v. Medipart, Inc., 976 F.2d 700, 708 n.7 (Fed. Cir. 1992) (relying
on the Uniform Commercial Code, which provides that a restriction may become a term of
the sale without explicit assent under certain circumstances). For some very sound argu-
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cases address the seed saving provision but not the research restriction
discussed below. Accordingly, it is unclear whether the validity of the
research restrictions would be similarly upheld.
Because the companies invest millions of dollars in the production of
genetically modified seeds, they view these intellectual property restric-
tions as critical to preserving their investment.123 Otherwise, because
seeds self-replicate, if farmers were allowed to keep them there would be
very little need to purchase additional seeds, thus threatening the compa-
nies' ability to recoup their investments.' 24 One court noted that
[w]ithout the prohibition against the saving of seed for replanting or
resale, Monsanto's patent would soon be rendered useless by virtue
of the potential for exponential multiplication of the seed containing
its patented technology. Given the risk of Monsanto's thus losing
control of its technology, the limited license of its technology was the
only reasonable alternative available to it if it hoped to garner a rea-
sonable return on its sizeable investment. 125
Lawsuits against farmers for saving seeds have been successful. For
instance, in two prominent cases, Monsanto sued Mississippi farmers who
planted Roundup Ready® soybean seeds and retained seeds for replant-
ing.126 The Court of Appeals for the Federal Circuit affirmed the lower
court's grant of summary judgment in favor of Monsanto, rejecting the
argument that Monsanto's patent rights had expired after the farmers
purchased the initial bags of seed.127
B. RESTRICTIONS ON RESEARCH
The licenses also prohibit research or experimentation and the growing
of these crops for research purposes.'28 The Court of Appeals for the
Federal Circuit appears to have found that these no-research policies are
"within the protection of the patent laws."' 129 However, because the is-
sues before the court focused on challenges to other aspects of the license
agreement and as part of an anticompetitive and antitrust analysis, it is
ments why the court's reliance on the UCC is misguided in these types of cases, see Mark
R. Patterson, Contractual Expansion of the Scope of Patent Infringement through Field-of-
Use Licensing, 49 WM. & MARY L. REV. 157, 186-88 (2007).
123. A survey by the American Seed Trade Association in 2005 showed that companies
invested more than $554 million in research and development of seed technologies. Brief
Amicus Curiae of the American Seed Trade Association in Support of Neither Party at 12,
Quanta Computer, Inc. v. LG Elecs., Inc., 553 U.S. 617 (2008) (No. 06-937), 2007 WL
3353100 at *12.
124. See Jason Savich, Note, Monsanto v. Scruggs: The Negative Impact of Patent Ex-
haustion on Self-Replicating Technology, 22 BERKELEY TECH. L.J. 115-16 (2007).
125. Monsanto Co. v. Scruggs, 249 F. Supp. 2d 746, 753 (N.D. Miss. 2001).
126. See, e.g., Monsanto Co. v. Scruggs, 459 F.3d 1328, 1333 (Fed. Cir. 2006); McFarling
H, 363 F.3d 1336, 1340 (Fed. Cir. 2004).
127. Scruggs, 459 F.3d at 1336 (noting that "[a]pplying the first sale doctrine to subse-
quent generations of self-replicating technology would eviscerate the rights of the patent
holder").
128. See, e.g., Monsanto Co. v. Scruggs, 342 F. Supp. 2d 568, 575 (N.D. Miss. 2004).
129. Scruggs, 459 F.3d at 1340 (citing district court's finding on summary judgment).
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unclear whether a specific and more rigorous challenge to the research
restriction itself would yield a similar result.130 This Article takes the po-
sition that such research restrictions violate public policy given the unique
problems created by genetically modified foods. Moreover, it is question-
able whether these restrictions would fall within the scope of the patent
claims. The use of the license term arguably allows the patent holder to
reach those who are not a party to the agreement.13'
Beyond the license restrictions, there are additional and broader limi-
tations on researchers' access to the necessary patent materials and data
with which to conduct research. 32 Scientists have complained that their
access to patented genetically modified plants for research is restricted
and that companies such as Monsanto, Pioneer, and Syngenta exert too
much control over independent researchers. 133 Thus, these scientists ar-
gue that they cannot test seeds, compare one company's seeds to an-
other's, or investigate the environmental effects of genetically modified
crops. 134 To do so requires permission from each patent holder of the
seed or gene required for testing; access to data and the publication of
data would also need to be negotiated. 35 Sometimes, in exchange for
receiving permission to do research on the seeds, the researcher must
submit any findings to the company for review prior to publication.1 36
These requirements and restrictions are inconsistent with scientists' obli-
gations to publish the results of publicly funded research. 137 Prior to the
advent of patent protection in this area, researchers could purchase and
test these products if they were commercially available, 38 just as they
continue to do for conventional seeds. 139
Indeed, a group of twenty-four scientists representing public research
institutions in seventeen states recently submitted a statement to the En-
vironmental Protection Agency (EPA), 140 complaining that "[a]s a result
of restricted access, no truly independent research can be legally con-
130. Id. at 1341.
131. See, e.g., Monsanto Co., 342 F. Supp. 2d at 575 (holding restrictions on research fell
within the scope of the patent monopoly and were lawful).
132. See A Seedy Practice, supra note 5, at 28.
133. See id.
134. Id.; see also Emily Waltz, Under Wraps, 27 NATURE BIOTECHNOLOGY 880, 880
(2009) ("Syngenta recently implemented a rule prohibiting any study that compares its
commercial crops to other companies' crops ... .
135. Stutz, supra note 11.
136. Andrew Pollack, Crop Scientists Say Biotechnology Seed Companies Are Thwart-
ing Research, N.Y. TiMEs, Feb. 20, 2009, at B3.
137. Waltz, supra note 134, at 881 ("Negotiations in 2008 between Monsanto and two
universities-North Dakota State University and the University of Minnesota-broke
down when Monsanto insisted on approving publication of any data on its newly commer-
cialized transgenic sugar beets ....").
138. Thomas W. Sappington et al., Commentary, Conducting Public-Sector Research on
Commercialized Transgenic Seed: In Search of a Paradigm That Works, GM CRoPs,
Mar.-Apr. 2010, at 55, 56 (2009).
139. Pollack, supra note 136, at B3.
140. Stutz, supra note 11.
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ducted on many critical questions regarding the technology."' 141 The
scientists submitted their statement anonymously, mindful that they were
criticizing an industry from which they require cooperation in order to
conduct their research.142
However, the identities of several of the participants have since been
revealed, and they include entomologists from the University of Minne-
sota, Cornell University, Purdue University, and North Dakota State
University, among others.' 43 The heart of the frustration felt by the
scientists is reflected in a comment by Professor Elson J. Shields of Cor-
nell, who stated that as a result of these research restrictions the industry
has "the potential to launder the data," and "[i]f your sole job is to work
on corn insects and you need the latest corn varieties and the companies
decide not to give it to you, you can't do your job."'144 Separately, there
are also reports that scientists are intimidated by the industry, and that
some have been personally and professionally threatened for publishing
data with which the industry did not agree. 145
The companies, on the other hand, take a different view. They assert
that they support academic research. 146 Monsanto, for instance, uses an
academic research license that permits certain kinds of research. 147 The
companies defend their need to manage public sector research in light of
government regulations relating to exports, experiments with precom-
mercial products, and protection of their substantial investments and in-
tellectual property. 148 They acknowledge that it is important to maintain
good relationships with academics because the companies rely on their
expertise and often engage them to conduct certain studies.' 49 The scien-
tists argue that these justifications are not credible and are largely the
producer's effort to minimize the chances that negative data or informa-
tion will be released about their products.150
141. Anonymous Public Comment to Meeting Notice, 73 Fed. Reg. 75,099-75,101 (Dec.
10, 2008), Docket No. EPA-HQ-OPP-2008-0836-0043 (Feb. 9, 2009, 1:54 PM), http://www.
regulations.gov/#!documentDetailD=EPA-HQ-OPP-2008-0836-0043. The text of the state-
ment reads as follows: "Technology/stewardship agreements required for the purchase of
genetically modified seed explicitly prohibit research. These agreements inhibit public
scientists from pursuing their mandated role on behalf of the public good unless the re-
search is approved by industry. As a result of restricted access, no truly independent re-
search can be legally conducted on many critical questions regarding the technology, its
performance, its management implications, IRM, and its interactions with insect biology.
Consequently, data flowing to an EPA Scientific Advisory Panel from the public sector is
unduly limited." Id.
142. Id.
143. Pollack, supra note 136, at B3.
144. Id.
145. Stutz, supra note 11.
146. See Waltz, supra note 134, at 882.
147. Id. at 881.
148. Id.; Pollack, supra note 136, at B3.
149. Waltz, supra note 134, at 882.




If patent law and its license restrictions permit producers of genetically
modified crops to restrict and control research on the health effects of
genetically modified foods, one may expect that there are checks in other
areas of the government to protect consumers. Unfortunately, that does
not appear to be the case. Outside of patent law, the regulatory policy
choices on genetically modified products represent the belief that these
products are not significantly different from their non-genetically engi-
neered counterparts and that they are not inherently dangerous.15' Thus,
their regulation occurs under statutes that were already in existence
before the arrival of genetically modified technology. 152 Scientists have
assumed that the genes from one organism can be extracted and moved
into another organism and that the gene will continue to operate exactly
the same way that it did in the original organism.' 53 The underlying as-
sumption is that the mere fact that these products were created using
biotechnology does not in itself create any unusual risks.1 54 Accordingly,
the approach was to focus on the ultimate product created and not the
process that was used to create it.' 55 But what if these assumptions are
inaccurate? Recent evidence suggests, for instance, that a gene may ex-
press itself differently in a new organism than it did in the donor organ-
ism and that the context and environment in which a gene has been
transferred may trigger certain unexpected reactions.' 56
The three main agencies involved in the regulation of genetically modi-
fied foods are the Environmental Protection Agency (EPA), the U.S. De-
partment of Agriculture (USDA), and the Food and Drug Administration
(FDA).157 The FDA regulates genetically modified organisms (GMOs)
that become food or drugs, the USDA regulates GMOs where they are
existing crops, and the EPA regulates genetically modified pesticide prod-
ucts.1 58 The shortcomings of the existing regulatory framework gov-
erning genetically modified products have been well documented and
analyzed by other commentators. 159 As such, this Article will only pro-
151. See Mandel, supra note 81, at 2242.
152. Id. at 2242-43.
153. Mark B. Gerstein et al., What is a Gene, post-ENCODE? History and Updated
Definition, 17 GENOME RES. 669, 672 (2007).
154. THE PEW INITIATIVE ON FOOD AND BIOTECHNOLOGY, GUIDE TO U.S. REGULA-
TION OF GENETICALLY MODIFIED FOOD AND AGRICULTURAL BIOTECHNOLOGY PROD-
ucrs, at i (Sept. 2001), http://www.pewtrusts.org/uploadedFiles/wwwpewtrustsorg/Reports/
FoodandBiotechnology/hhs biotech_0901.pdf.
155. Id.
156. See Van Tassel, supra note 88, at 222; see also Vanessa E. Prescott et al., Transgenic
Expression of Bean a-Amylase Inhibitor in Peas Results in Altered Structure and Immu-
nogenicity, 53 J. AGRIC. FOOD CHEM. 9023, 9029 (2005) (describing genetically modified
peas where animal testing revealed that the added protein was allergenic).
157. Mandel, supra note 81, at 2173.
158. Id. at 2216-17.
159. See, e.g., Mary Jane Angelo, Regulating Evolution for Sale: An Evolutionary Biol-
ogy Model for Regulating the Unnatural Selection of Genetically Modified Organisms, 42
WAKE FOREST L. REV. 93, 141-47 (2007); Mandel, supra note 81, at 2231-33.
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vide a brief overview of the regulatory scheme to orient the reader.
Regulation of transgenic plants is divided into two areas: (1) regulation
of the transgenic plant itself and (2) regulation of products derived from
the transgenic plant. 160 The first consideration under regulation of the
transgenic plant is whether it has been modified to produce a plant-incor-
porated protectant (PIP).161 A plant that produces a PIP is a plant that
has been engineered to produce its own pesticide, such as Bt corn.
162
Even if each of the agencies reviews a particular genetically modified
plant, as it currently stands, their evaluations are not focused on overall
human health. 163 Instead, for instance, the EPA and the USDA are eval-
uating the amount of pesticide residue in the plant, whether the plant is a
plant pest, and whether the amount of pesticide is at or below the level
deemed safe for consumption. 164 The producers of genetically modified
products submit data to the respective agencies when required, and much
of it is designated as confidential or trade secret information and not
shared with the public or with researchers. 165 Accordingly, some argue
that it is difficult to verify data that has been submitted to the govern-
ment in support of approvals.' 66
1. USDA
All transgenic plants are subject to regulation as a potential plant pest
by the U.S. Department of Agriculture-Animal and Plant Health Inspec-
tion Service (APHIS). Anyone who wants to import, transport interstate,
or release into the environment a "regulated article"'167 must apply for a
permit or notify APHIS that an introduction will be made. 168 If a permit
is sought, the applicant must submit an application with specific informa-
tion about the proposed release.' 69 APHIS then reviews the application
to evaluate the potential risks.17° APHIS can then issue the permit or
160. THE PEW INITIATIVE ON FOOD AND BIOTECHNOLOGY, supra note 154, at 2.
161. Id. at 8.
162. Id. at 12.
163. Id.
164. Id. at iii.
165. Waltz, supra note 134, at 882.
166. See THE PEW INITIATIVE ON FOOD AND BIOTECHNOLOGY, supra note 154, at 9-10.
167. "'Regulated articles' are defined as any organism which has been altered or pro-
duced through genetic engineering ... which [USDA] determines is a plant pest or has
reason to believe is a plant pest."' Id. at 9 (alteration in original) (citing 7 C.F.R. § 340.1
(2009)).
"Section 403 of the PPA defines a plant pest as 'a protozoan; a nonhuman animal; a para-
sitic plant; a bacterium; a fungus; a virus or viroid; an infectious agent or other pathogen,'
or similar articles that injure, damage, or cause disease in any plant or plant product." id.
168. Id. at 9-10.
169. Information required on a permit application includes the following: (1) donor
organism(s); (2) recipient organism(s); (3) vector or vector agent(s); (4) description of the
molecular biological mechanisms involved in the production of the regulated article; (5)
description of the activity of the modified genetic material in the regulated article; (6)
description of the purpose of the introduction; and (7) steps to control the article and
associated biologic materials. Id. at 10 (citing 7 C.F.R. § 340.4 (2009)).
170. APHIS evaluates whether the transgenic plant will "(1) expose other plants to
pathogens; (2) harm other organisms, including agriculturally beneficial organisms,
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deny it.17 1 When the plant is ready for commercial release, a person may
petition APHIS for nonregulated status. 172 APHIS, based on accumu-
lated evidence from the field trials, can make a determination that the
regulated article does not pose a risk as a plant pest and that the previ-
ously regulated article will no longer be regulated. 173
In several instances, the USDA has been accused of not observing its
regulations with sufficient rigor.174 In a series of cases, the Agency has
been criticized for deregulating genetically modified plants without first
conducting a proper assessment of the risks or for finding that there will
be no significant impact on the environment and obviating the need to
prepare an environmental impact statement. 175 Just recently, the Su-
preme Court ruled on a case where the USDA had not prepared an envi-
ronmental assessment before deregulating the growth of biotech
alfalfa.' 76 While the district court had entered an injunction banning the
growth of biotech alfalfa because of this violation, the Supreme Court
ruled that the genetically engineered alfalfa seeds could be planted on an
interim basis while the agency completed its environmental impact
statement.177
2. EPA
If a plant produces a PIP it will be regulated by both EPA, under the
Federal Fungicide Insecticide and Rodenticide Act (FIFRA),178 and the
USDA-APHIS, under the Plant Protection Act (PPA). 179 If the plant
does not produce a PIP it will be regulated only by the USDA-APHIS. 180
The EPA is concerned with the plant's pesticidal properties while the
USDA-APHIS is concerned with whether the plant is a "plant pest." 181
Under FIFRA, the EPA regulates to ensure that the pesticide will not
cause "unreasonable adverse effects on the environment,"'182 which are
defined as:
threatened and endangered species, and, in the case of plants that produce pesticides, orga-
nisms that are not the intended target of the pesticide (non-target organisms); (3) increase
weediness in another species with which it might cross; (4) have an adverse effect on the
handling, processing or storing of commodities; or (5) threaten biodiversity." Id.
171. See id. at 11.
172. Id. at 11-12.
173. Id. (citing 7 C.F.R. § 340.6 (2009)).
174. Mandel, supra note 81, at 2232.
175. See, e.g., Ctr. for Food Safety v. Vilsack, No. C 08-00484 JSW, 2009 WL 3047227, at
*9 (N.D. Cal. Sept. 21, 2009) (finding that APHIS failed to prepare an environmental im-
pact statement before deregulating a genetically engineered sugar beet); Int'l Ctr. for Tech.
Assessment v. Johanns, 473 F. Supp. 2d 9, 27-29 (D.D.C. 2007) (finding that APHIS failed
to, among other things, list genetically engineered bluegrass as a noxious weed and ignored
its own regulations).
176. Monsanto Co. v. Geertson Seed Farms, 130 S. Ct. 2743, 2750-51 (2010).
177. Id. at 2759-60.
178. THE PEW INITIATIVE ON FOOD AND BIOTECHNOLOGY, supra note 154, at 12.
179. Mandel, supra note 81, at 2229 tbl. 1.
180. Id.
181. Id. at 2237 tbl. 2.
182. THE PEW INITIATIVE ON FOOD AND BIOTECHNOLOGY, supra note 154, at 12 (citing
7 U.S.C. § 136a(c)(5) (2000)).
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(1) any unreasonable risk to man or the environment, taking into
account the economic, social, and environmental costs and benefits
of the use of any pesticide, or (2) a human dietary risk from residues
that result from a use of a pesticide in or on any food inconsistent
with the [standard under the] Federal Food, Drug, and Cosmetic
Act. 18 3
EPA regulation of transgenic plants that produce PIPs starts during the
developmental stagei t84 Prior to approval for commercial release, the
EPA regulates pesticides through either the notification process or exper-
imental use permits (EUP). 185 The size of a proposed field test will deter-
mine whether notification or an EUP is required. 186 When the product is
ready for commercial release, it must go through the EPA's pesticide re-
gistration process' 87 unless it qualifies for an exemption from registra-
tion.1 88 Finally, if residue from the pesticide produced by the plant
presents a human dietary risk resulting from its use on or in food, the
EPA is charged, under the Federal Food, Drug, and Cosmetic Act
(FFDCA), with setting tolerance levels for that pesticide. 18 9
3. FDA
Under the FFDCA, the FDA categorizes substances that are added to
foods as either food additives or "generally recognized as safe"
(GRAS). 190 This distinction bears significance because, while food addi-
tives require premarket review and approval by the FDA, 191 those cate-
183. Id. (alteration in original) (citing 7 U.S.C. § 136(bb) (2000)).
184. Regulations Under the Federal Insecticide, Fungicide, and Rodenticide Act for
Plant-Incorporated Protectants (Formerly Plant-Pesticides), 66 Fed. Reg. 37,772, 37,785
(July 19, 2001) (to be codified at 40 C.F.R. pts. 152, 174).
185. THE PEW INITIATIVE ON FOOD AND BIOTECHNOLOGY, supra note 154, at 12.
186. Notification is required for a field test of less than ten acres of land or one acre of
water, an EUP is required for a field test up to 5,000 acres, and field tests larger than 5,000
acres generally require full registration. Id. (citing 7 U.S.C. § 136(c) (2000)).
187. Id. at 13. To obtain a registration "the applicant must show that the pesticide
'when used in accordance with widespread and commonly recognized practice,. . . will not
generally cause unreasonable adverse effects on the environment."' Id. (alteration in orig-
inal) (citing 7 U.S.C. § 136a(c)(5) (2000)). "EPA's evaluation includes an assessment of
data from tests done by the producer of the pesticide according to EPA guidelines, and an
evaluation of whether a pesticide has the potential to cause adverse effects on humans,
wildlife, fish and plants." Id.
188. "FIFRA allows EPA to exempt from registration requirements a pesticide or cate-
gory of pesticides for which registration is not necessary to meet the goal of environmental
protection." Id. (citing 7 U.S.C. § 136w(b)(2) (2000)). "To qualify for an exemption ... a
pesticide must pose a low probability of risk to the environment . . . and be unlikely to
cause unreasonable adverse effects to the environment even in the absence of regulatory
oversight." Id. (citing 40 C.F.R. § 152.25 (2000)). "If a pesticide or its chemical residue
may appear in food, then it can only meet exemption criteria if it also meets the food safety
standard under the FFDCA that 'there is a reasonable certainty that no harm will result
from aggregate exposure to the pesticide chemical residue, including all anticipated dietary
exposures and all other exposures for which there is reliable information.'" Id. (citing 21
U.S.C. § 346a(c)(2)(A) (2000)).
189. Id. (citing 21 U.S.C. § 356a(a)(1) (2000)).
190. THE PEW INITIATIVE ON FOOD AND BIOTECHNOLOGY, supra note 154, at 20.
191. Id. (alteration in original) (citing 21 C.F.R. § 170.3(i) (2000)).
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gorized as GRAS require no FDA approval. ' 192 The FDA treats
genetically modified foods, which are not expressly provided for in the
FFDCA, as GRAS; as such, they are not subject to FDA approval. 193 It
is the manufacturer that determines whether a product is GRAS, without
review by the FDA.194 There is, however, a voluntary process by which
the manufacturer can seek guidance from the FDA on whether a sub-
stance is GRAS.195 Under this voluntary process, the determination of
safety rests with the manufacturer. 196
In short, neither premarket testing nor FDA approval is required
before genetically modified plant foods are sold to consumers. 97 Fur-
thermore, genetically modified foods are not required to be labeled be-
cause they are not considered substantially different from their
conventional counterparts. 198 Incidentally, this also raises a question
about how a product could be substantially equivalent to its non-geneti-
cally modified counterpart for FDA purposes, yet it had to have been
substantially different to receive a patent.199
D. TREATMENT OF GENETICALLY MODIFIED FOODS VERSUS DRUGS
The approach that the United States has taken to regulating genetically
modified foods stands in stark contrast to the regulation of drugs, which
are also ingested by most American consumers. The pharmaceutical in-
dustry is also an appropriate analogous point of reference because it too
relies heavily on patenting. 200 Unlike genetically modified foods, after
the patent issues on a drug (and in usual fashion the patent prosecution
process does not take into consideration the consequences of use of the
invention), there is a regulatory regime in place to approve drugs before
they reach the consumer.20' While not without its shortfalls, 20 2 FDA
oversight exists while tort law, through products liability actions, also
helps to identify those drugs that cause injury to consumers.20 3
Before a drug is approved, its manufacturer must establish to the FDA
192. Id. (citing 21 U.S.C. § 321(s) (2000); 21 CFR § 170.30 (2000)).
193. 21 U.S.C. § 321(s) (2000).
194. THE PEW INITIATIVE ON FOOD AND BIOTECHNOLOGY, supra note 154, at 21.
195. Id. (citing 21 C.F.R. § 107.35(c)(4) (2000)).
196. Id. at 20-21.
197. Van Tassel, supra note 88, at 241.
198. Mandel, supra note 81, at 2219.
199. Analysis of this question is beyond the scope of this Article. However, considera-
tion of the various standards involved would lead to a better understanding of how it may
be possible to reconcile these apparent contradictions. See supra note 81 and accompany-
ing text; see also MERGES ET AL., supra note 101, at 209 (noting that to meet the novelty
requirement under the Patent Act an invention must be different from that which already
exists).
200. See Christine D. Galbraith, Dying to know: A Demand for Genuine Public Access
to Clinical Trial Results Data, 78 Miss. L.J. 705, 757-58 (2009).
201. Victor E. Schwartz & Phil Goldberg, A Prescription for Drug Liability and Regula-
tion, 58 OKLA L. REV. 135, 141-31 (2005).
202. See Galbraith, supra note 200, at 712 (arguing that the results of clinical trial data
should be public).
203. Wyeth v. Levine, 129 S. Ct. 1187, 1200 (2009).
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that it is safe and effective for humans.20 4 Thus, the pharmaceutical com-
pany must file an Investigational New Drug Application (IND) prior to
conducting clinical trials with humans.20 5 The IND provides information
about earlier studies conducted with the drug in the laboratory and on
animals. 20 6 This is then followed by three stages of clinical trials using
human subjects.2 0 7 If the results of these trials indicate that the drug is
likely to be approved, the company will then file a New Drug Application
(NDA) with the FDA, providing the data and results from the clinical
trials. 20 8 Upon reviewing all of this data, the FDA will determine
whether the drug is safe, effective, and worthy of approval.20 9 While
these clinical trial results are generally treated as trade secrets by the
FDA and are not revealed to the public, 210 there is some level of assur-
ance in knowing that the FDA has reviewed the positive and negative
data about a drug before it is made available for public consumption.2 1 1
Such is not the case, however, with genetically modified products.212
Moreover, to the extent that there are flaws in the FDA process that
would permit approval of drugs that are nonetheless harmful to patients,
tort and criminal laws serve as a check on pharmaceuticals that may cause
harm. For instance, in 2004, the New York Attorney General filed suit
against the maker of Paxil® for misrepresenting the safety of the drug for
use in children and adolescents. 213 Thousands of products liability law-
suits were also filed accusing Merck & Co.'s Vioxx® of increasing the
risks of myocardial infarctions and stroke.214 The discovery of these side
effects was supported by a number of studies and publications in the sci-
entific literature.21 5 Several diet drugs have also been the subject of simi-
lar claims, resulting in class actions.2 1 6
With genetically modified foods, however, the tort system is not a feasi-
ble option. Since consumers are generally unaware that they have even
consumed a genetically modified food, it becomes very difficult to estab-
204. 21 U.S.C. § 355(d)(2), (5) (2006).
205. 21 C.F.R. § 312.20(b) (2008); see also Schwartz & Goldberg, supra note 201, at 142.
206. 21 C.F.R. § 312.22(c) (2008).
207. 21 C.F.R. § 312.21 (2008).
208. 21 U.S.C. § 355(b)(1) (2006); 21 C.F.R. § 314 (2008).
209. 21 U.S.C. § 355(d) (2006); 21 C.F.R. § 314.125(a) (2009).
210. Availability of Records and Information, 42 Fed. Reg. 3094 (Jan. 14, 1977).
211. But see Galbraith, supra note 200, at 705, 710-13 (identifying weaknesses in the
FDA review process).
212. Mandel, supra note 81, at 2218-21.
213. Complaint at 1, State v. GlaxoSmithKline, P.L.C., No. 905-03 (N.Y. Sup. Ct. filed
Feb. 13, 2003), 2003 WL 22023372.
214. In re Vioxx Prods. Liab. Litig., 401 F. Supp. 2d 565, 571 (E.D. La. 2005); see also
Merck Agrees to Settlement over Vioxx Ads, N.Y. TIMES, May 21, 2008, at C3.
215. In re Vioxx Prods. Liab. Litig., 401 F. Supp. 2d at 571.
216. See, e.g., In re Diet Drugs Prods. Liab. Litig., 282 F.3d 220, 225 (3d Cir. 2002);
Vioxx Clinical Study, CLINICAL STUDY RESULTS.ORG, http://www.clinicalstudyresults.org/
search/?company-id=40&-drug-name id=438-r=1&submitted=1&page=1 (last visited Oct.
31, 2010); Wyeth Seeks to Delay Payments to Some in Fen-Phen Settlement, N.Y. TIMES,
May 6, 2004, at C8.
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lish a causal connection between the product and any resulting injury.217
Moreover, without the requisite research to evaluate genetically modified
foods, it is almost impossible for a plaintiff to show that the risk of harm
was foreseeable, 218 or conversely, independent research could also reveal
that the products pose very little risk. Further drawing on the food versus
drug comparison, in a subsequent section this Article draws an analogy
between regulatory treatment of generic drugs and genetically modified
foods, suggesting that the FDA's assumptions about the equivalence of
genetically modified foods, at best, does not alleviate the need for inde-
pendent research on these substances and, at worst, could be faulty.2 19
E. COMPARISON TO THE EUROPEAN APPROACH
Other countries have taken a different approach from the United
States in light of the lack of knowledge about genetically modified
foods. 220 European patent law, for instance, considers the morality of the
invention in assessing suitability for patenting.221 The European ap-
proach to genetically modified products has also been much more cau-
tious. Indeed, many European countries have banned the planting of
genetically modified crops222 and restricted importation of products such
as bioengineered corn from American companies like Monsanto, Dow
AgroSciences, Pioneer Hi-Bred, and Syngenta.223 European countries
tend to view genetically modified foods as "Frankenstein food. ' 224 The
French government, for instance, banned genetically modified crops in
2008.225 The European Commission is now considering a proposal to al-
low individual member countries to decide whether they wish to grow
genetically modified crops.226
IV. PATENT OVERREACHING
While the predominant narrative supporting the patent system is that
patents exist to encourage innovation, we often overlook the fact that the
217. For a thoughtful analysis of genetically modified products and the tort system see
Katharine Van Tassel, The Introduction of Biotech Foods to the Tort System: Creating a
New Duty to Identify, 72 U. CIN. L. REV. 1645, 1678-85 (2004).
218. Id. at 1684-86.
219. See infra Part IV.B.
220. Japan has chosen to heavily regulate genetically modified foods because of their
unknown consequences. See Paul J. Heald & James Charles Smith, The Problem of Social
Cost in a Genetically Modified Age, 58 HASTINcS L.J. 87, 88 (2006). Similar to South Ko-
rea, Australia, and New Zealand, Japan requires labeling for food products containing ge-
netically modified foods. Id. at 112.
221. Jerzy Koopman, The Patentability of Transgenic Animals in the United States of
America and the European Union: A Proposal for Harmonization, 13 FORDHAM INTELL.
PROP. MEDIA & ENT. L.J. 103, 202 (2002).
222. Langreth & Herper, supra note 57, at 66.
223. Kanter, supra note 51, at B4.
224. David G. Owen, Bending Nature, Bending Law, 62 FLA. L. REV. 569, 575-76
(2010).
225. Kanter, supra note 51, at B4.
226. Id.
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primary concern of the patent system is the public interest.227 The consti-
tutional clause granting Congress the power to establish the patent laws
recognizes the importance of "promot[ing] the [p]rogress of [s]cience. 228
This underlying premise is consistent with intellectual property principles
that preserve information in the public domain unless it can specifically
be claimed under one of the branches of intellectual property law, sup-
port incentives for ifivestments in research, and recognize the full disclo-
sure of information to the public as a worthy exchange in the patent
bargain with an inventor.2 29
As part of that bargain, Congress (and the Founding Fathers) could not
have intended that the public benefit received from disclosure on a patent
would be less than the value of the patent. 230 If that were the case, the
inventor would receive a windfall. As a court has noted, "[t]he far-reach-
ing social and economic consequences of a patent ... give the public a
paramount interest in seeing that patent monopolies ... are kept within
their legitimate scope."' 23' Accordingly, patents on genetically modified
plants that not only grant a monopoly to the patent holder but also re-
strict any research that may identify risks to the public health from use of
these patented materials go too far. According to the Supreme Court:
"[i]nnovation, advancement, and things which add to the sum of useful
knowledge are inherent requisites in a patent system... [t]his is the stan-
dard expressed in the Constitution and it may not be ignored. ' 232 If pat-
ent laws are intended to promote the progress of science, then it seems
intuitive that active discouragement of independent research does not
support scientific advancement and, ultimately, is inconsistent with the
underlying goals of patent law and policy. If the goal is to encourage
innovation, there cannot be innovation without scientific inquiry and
research.
A. PROTECTING OR OVERREACHING?
It is important to be mindful of overreaching intellectual property laws
that provide "protection" above and beyond that which was intended.
While in other contexts this may be considered abuse by the individual
rights holder, here, however, the system-the courts and the legislature-
has created and sanctioned the conduct. Accordingly, it is not the indi-
227. See Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 330-31 (1945)
("The primary purpose of our patent system is not reward of the individual but the ad-
vancement of the arts and sciences. Its inducement is directed to disclosure of advances in
knowledge which will be beneficial to society; it is not a certificate of merit, but an incen-
tive to disclosure."); see also United States v. Line Material Co., 333 U.S. 287, 320 (1948)(Douglas, J., concurring).
228. U.S. CoNsT. art. I, § 8, cl. 8.
229. James Bradshaw, Gene Patent Policy: Does Issuing Gene Patents Accord with the
Purposes of the U.S. Patent System?, 37 WILLAMErE L. REV. 637, 645 (2001).
230. See, e.g., In re Fisher, 427 F.2d 833, 839 (C.C.P.A. 1970) (noting that the scope of a
patent must be commensurate with the scope of what the patentee has given the public).
231. Mayo Clinic Jacksonville v. Alzheimer's Inst. of Am., Inc., 683 F. Supp. 2d 1292,
1295 (M.D. Fla. 2009).
232. Graham v. John Deere Co. of Kansas City, 383 U.S. 1, 6 (1966).
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vidual corporations that are to be blamed for protecting their interests
but rather the laws that serve as the thumb on the scale in their favor and
to the potential detriment of the public interest. In the case of genetically
modified foods, the license agreements, in addition to the patent rights,
create cause for concern and reflect another example of intellectual prop-
erty laws providing far greater protection than contract law alone would
provide in a typical license.
The "bag tag" licenses with the seeds are similar to "shrink-wrap" li-
censes used on software. The terms of the license are on the product, and
the consumer impliedly accepts the terms of the license by purchasing
and using the product.233 In copyright law, courts have upheld "shrink-
wrap" and "click-wrap" licenses.234 Often these cases rely on the fact
that the consumer was made aware of the terms at the time of sale, ac-
knowledged that awareness, and had an opportunity to decline the terms
by, for instance, returning the product.235 It is not clear that these terms
are met when a notice is posted on a bag of corn seeds.236 Furthermore,
it is now nearly impossible for a commodity farmer to avoid using seeds
from any of the companies that require these licenses. 237
It is therefore not unusual that intellectual property laws are used to
restrict consumers or shield information from the public. Granted, there
are often legitimate reasons to do so, and trade secret law in conjunction
with a complicated regulatory scheme allows companies to keep proprie-
tary information from public view. 238 Indeed, before it was acceptable to
protect plants with patents, producers used trade secret law to protect
their innovations.239 In another example involving copyright law, the
Digital Millenium Copyright Act (DMCA) declares it copyright infringe-
ment to "circumvent a technological measure" that is used to encrypt or
protect information in digital form.240 This meant, for instance, that a
college professor may not make a one-minute clip from a movie on a
DVD to teach a class, even though without the legislation that kind of use
would probably be permissible fair use. Accordingly, the DMCA has
been criticized for going too far to protect copyright owners at the ex-
pense of the public. 2 41 Recognizing that the DMCA anticircumvention
233. Specht v. Netscape Commc'ns Corp., 306 F.3d 17, 22 n.4 (2d Cir. 2002); see also
Bowers v. Baystate Techs., Inc., 320 F.3d 1317, 1324 (Fed. Cir. 2003) (upholding the validity
of shrinkwrap licenses).
234. See, e.g., ProCD, Inc. v. Zeidenberg, 86 F.3d 1447, 1952-53 (7th Cir. 1996); see also
Patterson, supra note 122, at 189.
235. Patterson, supra note 122, at 189-90.
236. See id.
237. See, e.g., supra notes 3, 55-58 and accompanying text.
238. See Elizabeth A. Rowe, Striking a Balance: When Should Trade-Secret Law Shield
Disclosures to the Government?, 96 IowA L. REV. 791, 807-15 (2011).
239. See supra Part II.A.2.
240. 17 U.S.C. § 1201(a)(1)(A) (2006).
241. Christina Bohannan, Reclaiming Copyright, 23 CARDOZO ARTS & ENT. L.J. 567,
591 (2006); John B. Clark, Copyright Law and the Digital Millennium Copyright Act: Do
the Penalties Fit the Crime?, 32 NEW ENG. J. ON CRIM. & Civ. CONFINEMENT 373, 402-03
(2006); Kevin C. Earle, No-Copy Technology and the Copyright Act: Has the Music Indus-
try Been Allowed to Go Too Far in Diminishing the Consumers' Personal Use Rights in the
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provisions go too far in reaching otherwise noninfringing conduct, the
Copyright Office has recently issued certain exemptions to the provisions;
thus, a college professor may now create the clip, and a cell phone user
can "unlock" his or her phone to be used with a network carrier of his or
her choice. 242
B. FORBIDDING RESEARCH-CROSSING THE LINE?
The research restrictions that are the focus of this Article are even
more troubling than the kinds of limitations imposed under copyright
law. The fact that these no-research clauses could pose a direct threat to
public health and safety and because they involve our food supply, it
makes the call for action all the more compelling. These licenses provide
greater restrictions than patent law itself allows. Some commentators
have argued, for instance, that the license terms are inconsistent with the
patent exhaustion doctrine, which allows the purchaser of a patented
product to use it without owing further duties to the patent owner.243
Why is it that one can purchase a car with patented components, take it
apart, repair it, and sell it, but a farmer cannot do the same with his or her
seeds? As the editors of Scientific American Magazine have argued,
"when scientists are prevented from examining the raw ingredients in our
nation's food supply or from testing the plant material that covers a large
portion of the country's agricultural land, the restrictions on free inquiry
become dangerous."'244 It should be apparent that knowledge restrictions
involving food and its safety ought to receive closer scrutiny than other
consumer commodities, or at least as much as that received by
pharmaceuticals.
In the analogous context of pharmaceuticals, congressional action2 45
and current Supreme Court jurisprudence allow others to conduct re-
search on patented drugs and medical devices as long as it is the kind of
research that is reasonably related to a submission to the FDA.246 Since
this exemption allows even commercial competitors to experiment with-
out infringing, it probably also allows academic researchers to do so and
Digital World?, 2 J. MARSHALL REV. INTELL. PROP. L. 337, 352 (2003); Thomas A. Mitch-
ell, Note, Copyright, Congress, and Constitutionality: How the Digital Millennium Copy-
right Act Goes too Far, 79 NOTRE DAME L. REv. 2115, 2133 (2004).
242. Exemption to Prohibition on Circumvention of Copyright Protection Systems for
Access Control Technologies, 75 Fed. Reg. 43,825 (July 27, 2010) (to be codified at 37
C.F.R. pt. 201).
243. See, e.g., Kevin Rodkey, Exhaustion and Validity of Single-Use Licenses for Trans-
genic Seeds in the Wake of Quanta v. LG Electronics, 19 FED. Cm. B.J. 579, 603-04 (2010);
Jon Sievers, Note, Not So Fast My Friend: What the Patent Exhaustion Doctrine Means to
the Seed Industry After Quanta v. LG Electronics, 14 DRAKE J. AGRIC. L. 355, 371-74
(2009).
244. A Seedy Practice, supra note 5, at 28.
245. 35 U.S.C. § 271(e)(1) (1994) (creating a "safe harbor" exemption for research).
246. Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193, 202 (2005) (interpreting
section 271's safe harbor provision to extend to "all uses of patented inventions that are




takes away a patent holder's ability to claim infringement on such activi-
ties.24 7 If Congress and the Court have seen fit to issue this kind of ex-
emption for patented pharmaceuticals, a similar move for genetically
modified foods seems logical. Indeed, it appears that the pharmaceutical
exemption has already been interpreted broadly to reach beyond
drugs.248
This suggests that the research conduct that is prohibited through the
license agreements and patent law may be otherwise permissible, given
the broad interpretation of the Supreme Court's holding in Merck v. In-
tegra. These restrictions may be ripe for congressional legislation that
would make them void as a matter of public policy.24 9 Alternatively,
Merck and the direction that we are headed with drug research suggest
that courts (even without congressional action) may consider, on a case-
by-case basis, how to deal with research restrictive licenses in cases in-
volving genetically modified foods. One could, for instance, envision liti-
gation similar to the Myriad case involving BRACA1 where a group of
academic researcher plaintiffs (such as the group that submitted the
anonymous statement to the EPA) challenge their inability to conduct
basic research to determine whether genetically modified foods are safe
to consume.
2 50
Restricting research has far-reaching consequences that go beyond
merely protecting the patent holder's intellectual property rights and also
insulates the patent holder from the potentially harmful consequences of
his or her invention. Without sufficient research to expand the state of
knowledge about genetically modified products that enter consumers'
bodies, consumers and legislators are unable to make choices about
whether and to what extent to consume or regulate these products. Fur-
thermore, unlike with pharmaceuticals, if injury were to occur, potential
plaintiffs are, in effect, locked out of the tort system.25 1 Without re-
search, the state of knowledge cannot establish foreseeability of harm,
and because plaintiffs bear the burden of proving foreseeability, the pat-
ent-holding manufacturer is insulated from liability.252 Thus, the results
are failures in the system where checks and balances are eliminated, and
the power of a patent does not serve the progress of science or enrich the
public knowledge, but instead enriches and insulates a patent holder at
the expense of the public.
247. See Christina M. Gagnier, Comment, Running Cases Through a Merck Sieve: Bi-
opharmaceutical Research in the Wake of Merck v. Integra, 12 INTELL. PROP. L. BULL. 159,
172-73 (2008).
248. See, e.g., Classen Immunotherapies, Inc. v. King Pharm., Inc., 466 F. Supp. 2d 621,
625 n.2 (D. Md. 2006) (applying exemption to "research tools"); Classen Immunotherapies,
Inc. v. Biogen IDEC, 381 F. Supp. 2d 452, 456 (D. Md. 2005) (protecting the gathering of
vaccine data after the vaccine has been approved by FDA); Genentech, Inc. v. Insmed,
Inc., 436 F. Supp. 2d 1080, 1094 (N.D. Cal. 2006) (protecting activities conducted for com-
mercial purposes where the results were used to get FDA approval).
249. See discussion infra notes 279-82 and accompanying text.
250. See discussion infra notes 286-91 and accompanying text.
251. See Van Tassel, supra note 217, at 1678-85.
252. See id.
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Even without patent law and contractual research restrictions, it has
already been suggested that scientific research and results made public by
manufacturers can be questionable. 253 For example, when required to
produce studies, manufacturers sometimes contract with university scien-
tists or other laboratories, and these contracts generally allow the manu-
facturer to retain ownership of the results and to control its
publication. 254 This allows for adverse research findings to be concealed
or for further studies to be commissioned that will produce more positive
results.2 55 This practice is consistent with some of the complaints that
have already been lodged by academic scientists against the industry.256
Further, it makes the case for much more research, by a wider group of
scientists, in an area about which we know so little, even more persuasive.
Finally, another example from the pharmaceutical industry provides
further reason to question regulators' assumptions about genetically
modified foods. As noted earlier, these products are not required to be
labeled because they are assumed to be "essentially the same" as their
non-genetically modified counterparts. 257 Similarly, generic drugs are as-
sumed to be the same as their branded counterparts as long as they con-
tain bioequivalent levels of the active ingredient.2 58  However,
researchers have noted that generic drugs are not the same as the brand-
name drug because, for example, they have different inactive ingredients
and patients sometimes have different reactions to the generic drug than
to the brand-name drug.259 Accordingly, this suggests a further threat to
public health from the information void surrounding genetically modified
foods. 260 Not only might the assumption of equivalence between the ge-
netically modified and non-genetically modified foods be faulty but, un-
like with a generic drug, the consumer is not aware that he or she is
consuming the genetically modified (generic) version of a food and can-
not make an informed decision about whether to switch to the non-genet-
ically modified (branded) version in case of a negative outcome. 261
253. See supra notes 138-46 and accompanying text.
254. See, e.g., Gail Charnley & Jacqueline Patterson, Use of Human Subjects Data for
Regulating Chemical Exposures, 33 ENVTL. L. REP. 10,923, 10,927 (2003) (referring to pes-
ticide manufacturers' use of contract laboratories to conduct testing).
255. See, e.g., David Blumenthal et al., Withholding Research Results in Academic Life
Science: Evidence from a National Survey of Faculty, 277 J. AM. MED. Ass'N 1224, 1224
(1997); Drummond Rennie, Editorial, Thyroid Storm, 277 J. AM. MED. Ass'N 1238,
1242-43 (1997); Steven A. Rosenberg, Secrecy in Medical Research, 334 N. ENG. J. MED.
392 (1996); Wagner, supra note 6, at 1707-08.
256. See supra notes 140-45 and accompanying text.
257. See supra notes 151-52, 198 and accompanying text.
258. See Susan J. Shaw & Adam L. Hartman, The Controversy Over Generic An-
tiepileptic Drugs, 15 J. PEDIATRIC PHARMACOLOGY & THERAPEUTICS 81, 82 (2010).
259. See id. at 87; see also Lesley Alderman, A New Disquiet About Generic Drugs,
N.Y. TIMES, Dec. 19, 2009, at B6.
260. See supra notes 90, 153-56 and accompanying text.
261. See supra notes 90, 153-56 and accompanying text.
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C. PROPOSING A "PATENT OVERREACH" DOCTRINE AND
GREATER ACCESS
Professor Margo Bagley has argued that the "patent first, ask questions
later" approach used in the United States is bad policy.262 The issues that
arise with patenting genetically modified foods support her argument. In-
deed, it illustrates an extreme angle on the problem because it represents
patenting first, asking questions later, and shutting off the research neces-
sary to answering the question. While patent law generally does not con-
cern itself with morality, if it exists to serve (or at least not harm) the
public interest, then we ought to be troubled by the implications of this
new direction.
The Supreme Court has recognized that "Congress in the exercise of
the patent power may not overreach the restraints imposed by the stated
constitutional purpose. Nor may it enlarge the patent monopoly without
regard to the innovation, advancement or social benefit gained
thereby. '263 The patent system should therefore be imbued with a sense
of social responsibility, such that the powers granted under a patent are
not stretched to such an extent that the public interest is subjugated to a
point where public health and safety may be compromised. This is a
broader consideration than moral utility or other such considerations that
are specific to the grant of a patent to an inventor.
One way to ensure that the public interest is directly considered would
be to create a judicial doctrine to be used by courts when determining
whether certain restrictions are within a patent right. It would serve as a
limiting principle to avoid undue expansion of a patent's power to ex-
clude. This Article thus suggests and coins a "patent overreach" doctrine
that courts could rely on in refusing to enforce license agreements that
restrict research. This outcome is justified where, on balance, the public
interest in access to more information about the effects of genetically
modified products outweighs any legitimate interest in enforcement of
these agreements. Such agreements, at worst, may have the effect of con-
cealing substantial health and safety dangers and, at best, limit or control
the body of independent research available on genetically modified
foods.
The patent overreach doctrine is consistent with the existing doctrine
of patent misuse that forbids an impermissible broadening of a patent
beyond the scope of the patent rights.264 While generally used in the an-
titrust context, the patent misuse doctrine has some flexibility to restrain
practices that go beyond anticompetitive conduct and to broader viola-
tions of public policy.265 Thus, one possible iteration of the patent over-
262. Bagley, supra note 108, at 474-75.
263. Graham v. John Deere Co. of Kansas City, 383 U.S. 1, 5-6 (1966).
264. Monsanto Co. v. Scruggs, 459 F.3d 1328, 1339 (Fed. Cir. 2006); Va. Panel Corp. v.
MAC Panel Co., 133 F.3d 860, 868 (Fed. Cir. 1997); Mallinckrodt, Inc. v. Medipart, Inc.,
976 F.2d 700, 708 (Fed. Cir. 1992).
265. See SmithKline Beecham Corp. v. Apotex Corp., 247 F. Supp. 2d 1011, 1047 (N.D.
I11. 2003) (Posner, J.), aff'd, 365 F.3d 1306 (Fed. Cir. 2004), vacated en banc, 403 F.3d 1328
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reach doctrine could be an expansion of the patent misuse doctrine to
cover conduct that goes beyond the scope of a patent and which is con-
trary to the public interest, such as undue restrictions on scientific re-
search or inquiry. Where patent overreaching violates our sensibilities
about justice and fairness and potentially threatens public health and
safety, courts (and the legislators in their own context) should take notice
in order to protect the public interest. As several members of the Su-
preme Court have noted, sometimes too much patent protection can ob-
struct rather than promote scientific progress.2 66
Beyond addressing enforcement of the license restrictions, the greater
problem of researchers' access to the patented genetically modified prod-
ucts will also need to be addressed in a meaningful way. PVP certificates
specifically provide an exemption for bona fide research.2 67 A similar
exemption for plant utility patents is worth considering, as it would both
allow the patent holder to exclude others yet permit independent re-
search. Similar exemption schemes are already recognized and in place
under the patent law for analogous inventions that involve public health
and safety.2 68 Congress has created exemptions from patent infringement
for germplasm in the PVPA,269 for development of generic drugs,270 and
for doctors using patented surgical procedures. 271 The research exemp-
tion for pharmaceuticals and medical devices, for instance, permits the
balancing of the same kinds of public interests that are at issue here.272
While easing the license restrictions would mean that scientists can ac-
cess the products through farmers without either party being liable for
patent infringement, direct access from the companies may continue to be
an issue unless private arrangements can be made. So far, the seed com-
panies will not agree to remove the "bag tag" restrictions on research.
However, they have expressed a willingness to enter into academic li-
censes with researchers.2 73 A public repository could be another option
as a source of seeds for bona fide research. Indeed, the PVPA requires
applicants for plant variety protection to deposit seeds or other reproduc-
(Fed. Cir. 2005); C.R. Bard, Inc. v. M3 Sys., Inc., 157 F.3d 1340, 1372 (Fed. Cir. 1998)
("Patent misuse is viewed as a broader wrong than antitrust violation .... ); Mallinckrodt,
Inc., 976 F.2d at 704 ("The concept of patent misuse arose to restrain practices that did not
in themselves violate any law, but that drew anticompetitive strength from the patent right,
and thus were deemed to be contrary to public policy.").
266. See, e.g., Bilski v. Kappos, 130 S. Ct. 3218, 3254-55 (2010) (Stevens, J. concurring);
Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124, 127 (2006).
267. 7 U.S.C. § 2544 (2006).
268. See supra Part II.A.3.
269. Id.
270. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-
417, 98 Stat. 1585 (codified as amended in scattered sections of 21 U.S.C. and 35 U.S.C.).
271. 35 U.S.C. § 287(c)(1) (2006) (exempting health care professionals from infringe-
ment of certain patented medical techniques).
272. Id.
273. In response to the complaint to the EPA, the seed companies have expressed an
interest in being more cooperative with researchers. However, researchers are skeptical




tive material in a public repository.2 74 However, the Supreme Court, in
dicta, has stated that the public has no right to seeds deposited in connec-
tion with applications for plant variety protection during the term of pro-
tection.2 75  Examination of operations at these public repositories
confirms the Supreme Court's statement that seeds deposited under certi-
fication are not released to the public without the consent of the certifi-
cate holder. 276 Thus, options to create access are not without hurdles and
will require thoughtful and balanced consideration.
Finally, even if the end-products containing the genetically modified
substances may be commercially available and thus accessible to re-
searchers, this does not solve the problem. Because genetically modified
products are not labeled, 277 a researcher walking into the supermarket to
purchase the product is presumably in the same position as other consum-
ers in that he or she is unable to identify the genetically modified foods.
Perhaps, unlike the consumer, the researcher could perform tests after
making the purchase to identify the components of the food product.
However, this nonetheless creates a hurdle and a burden. Furthermore,
because the end-product will be a combination of substances, it may be
difficult to sufficiently isolate the genetically modified material and its
effect.278 Accordingly, this option does not provide a viable substitute for
access to genetically modified materials that may be subject to the no-
research restrictions.
D. THE LARGER ISSUE OF PUBLIC POLICY AND PATENTING
The protection of public health and safety may be the most important
in the hierarchy of public policies. Several states have recognized, for
instance, that it is against the public interest to enter into settlement
agreements that shield information about dangers to the public's health
and safety.2 79 Similar public policy carve-outs have also been made in the
employment law area to permit whistle-blowing by employees despite
their having signed confidentiality agreements. 280 One legislative option
would be for Congress to rule these kinds of contracts that restrict re-
search void as a matter of public policy. However, until that happens
courts could, relying on the patent overreach doctrine, find that these
contracts violate the public interest.
274. Chen, supra note 38, at 140-41.
275. J.E.M. AG Supply, Inc. v. Pioneer Hi-Bred Int'l, Inc., 534 U.S. 124, 143 (2001)
(stating that the PVPA "requires a deposit of seed in a public depository ... but neither the
statute nor the applicable regulation mandates that such material be accessible to the gen-
eral public during the term of the PVP certificate").
276. Chen, supra note 38, at 140-41.
277. See supra note 257 and accompanying text.
278. See supra notes 98-99 and accompanying text.
279. See Elizabeth E. Spainhour, Unsealing Settlements: Recent Efforts to Expose Settle-
ment Agreements That Conceal Public Hazards, 82 N.C. L. REV. 2155, 2158-61 (2004) (dis-
cussing state laws, like Florida's, that declare private settlements that conceal public
hazards void as a matter of public policy).
280. See EMPLOYMENT LAW § 8.9, at 262 (Mark A. Rothstein et al. eds., 2d ed. 1999)
(discussing the erosion of the employment at will doctrine).
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According to the Second Restatement of Contracts, a contract is unen-
forceable for public policy reasons if either "legislation provides that it is
unenforceable or the interest in its enforcement is clearly outweighed in
the circumstances by a public policy against the enforcement of such
terms. '281 Thus, in this instance, the public interest in promoting inde-
pendent research on the health and safety effects of foods should out-
weigh the producer's interest in controlling the state of adverse
information available about its product. Indeed, the last time Congress
considered and debated the balance between protection for seed produc-
ers and the public, under the PVPA, it demonstrated a clear preference
for and recognition of the importance of research.2 82
The problem identified in this Article illustrates a larger question in
patent policy: how do we reconcile patent rights with the public interest
when the patent rights may threaten public health and safety? Similar
concerns have been raised about the patenting of human genes.283 The
genes associated with breast cancer, BRACA1 and BRACA2, are owned
and patented by Myriad Genetics. 284 Myriad's control over these genes
have been widely criticized for prohibiting independent research on the
genes, thus interfering with women's health and physician's treatment
practices. 285 Indeed, a few months ago, a New York district court granted
a victory to the American Civil Liberties Union and other re-
searcher-plaintiffs2 86 who challenged the validity of Myriad's patents.287
The case exemplifies the concern, as with the genetically modified prod-
ucts, that a patent holder has the power to impede research that could
potentially harm the public.2 88
This Article recommends a solution-based approach focused on the
larger, macro issues about obligations and policies of the patent system,
rather than the more specific questions about the propriety of issuing pat-
ents on specific inventions or the class of inventions comprising geneti-
cally modified substances. It is important to recognize and balance the
interests of all the stakeholders involved here. Inventors and businesses
need to protect their investment in research and development. Accord-
ingly, this is by no means a call to eliminate these patents. However,
281. RESTATEMENT (SECOND) OF CONTRACTS § 178 (1981).
282. See supra Part II.A.3.
283. See, e.g., Eric D. Zard, Comment, Patentability of Human Genetic Information:
Exploring Ethical Dilemmas Within the Patent Office and Biotechnology's Clash with the
Public Good, 6 U. ST. THOMAS L.J. 486, 504-11 (2009) (discussing opposing sides of the
controversy on gene patenting); Brian Zadorozny, Comment, The Advent of Gene Patent-
ing: Putting the Great Debate in Perspective, 13 SMU SCI. & TECH. L. REV. 89, 104-13
(2009) (same).
284. Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d
181, 181 (S.D.N.Y. 2010).
285. Complaint at 29, Ass'n for Molecular Pathology, 702 F. Supp. 2d 181 (No. 09-CV-
04515), 2009 WL 1343027, at *29.
286. These plaintiffs are researchers who received cease and desist letters from Myriad
for conducting research using the genes. Id.
287. Ass'n for Molecular Pathology, 702 F. Supp. 2d at 238 (granting summary judg-
ment in favor of plaintiffs and against Myriad).
288. See id. at 206-11.
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because the public's interest must also be safeguarded, one would, at a
minimum, see the logic in removing research restrictions.
Some commentators have suggested that perhaps we should change the
way patents are issued in these cases by, for instance, tightening the util-
ity standard.289 However, this problem requires a larger scale policy pre-
scription. For one thing, it is not merely the issuance of the patents that
contribute to the problem, but the licenses as well. Further, the nature of
these products also crosses over from the patent law and policy into other
regulatory arenas, and beyond law to science.2 90 The call to modify the
existing regulatory scheme291 is also likely to be a politically difficult
route.292 However, Congress has at times revised the patent laws to re-
spond to particular problems,293 indicating that such a path is indeed fea-
sible when there is congressional will.294
V. CONCLUSION
There is currently a void in the scientific knowledge relating to the ef-
fects of genetically modified foods on human health and the environment.
Patent law perpetuates that void by allowing patent holders to control
and restrict independent research in the area. Accordingly, this Article
analyzes how these research restrictions are contrary to the public inter-
est and inconsistent with the underlying goals of patent law. The Article
concludes that, on balance, the public interest in promoting independent
research on the health and safety effects of foods should outweigh the
patent holder's interest in controlling the state of adverse information
available about its product. It recommends that courts use a "patent
overreach" doctrine to rein in these restrictions where public health and
safety may be threatened. This would serve as a limiting principle to
avoid undue expansion of a patent's power to exclude.
289. See, e.g., Zachary Lerner, Comment, Rethinking What Agriculture Could Use: A
Proposed Heightened Utility Standard for Genetically Modified Food Patents, 55 U. KAN.
L. REv. 991, 1014-20 (2007).
290. Thus, among the many possible approaches to this problem, one could consider
requiring additional regulatory input or involvement before and after patent issuance. The
patent system as it currently exists, with patent examiners as the gatekeepers, is not
equipped to make determinations about whether a genetically modified invention will not
only meet the patenting standards but also the effect of the invention on environmental
safety and public health. Another consideration may be an EPA requirement that all seeds
be available to independent researchers prior to approving their sale.
291. See, e.g., Mandel, supra note 81, at 2258-59 (arguing in favor of new regulations).
292. See, e.g., Debra M. Strauss, The International Regulation of Genetically Modified
Organisms: Importing Caution into the U.S. Food Supply, 61 FOOD & DRUG L.J. 167, 188(2006) ("Congress does not appear to be supporting initiatives to address food safety con-
cerns and to tighten the regulatory process for bioengineered food in the United States.")
293. See, e.g., Biotechnological Process Patent, Pub. L. No. 104-41, 109 Stat. 351 (codi-
fied as amended at 35 U.S.C. § 103(b) (2006)) (revising process for biotechnology patents);
see also 35 U.S.C. § 273 (2006) (creating defense to patent infringement).
294. Accordingly, one modification of the existing patent law framework could require
that these types of plant inventions be eligible only for plant patents, not utility patents. Of
course, a complicating factor would be treatment of genetically modified animals as food
that would also need to be part of any comprehensive schematic solution in this area.
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The Article also calls for continuing discourse and consideration of the
larger questions about reconciling patenting with public policy, and pat-
enting with science and research. Congress and the courts must begin to
pay attention to the role of patenting in limiting, rather than promoting,
the progress of science, especially when public health and safety is
implicated.
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